T 372 is a brand name for a drug containing amphetamine and dextroamphetamine, similar to Adderall [1]. Both medications are stimulants used to treat attention deficit hyperactivity disorder (ADHD) [1].
What is the difference between T 372 and Adderall?
The primary difference lies in their formulation and potentially their inactive ingredients, which can affect how the medication is absorbed or tolerated by some individuals [1]. Both contain the same active pharmaceutical ingredients, amphetamine and dextroamphetamine, but their specific pill compositions can vary [1].
Who makes T 372 and Adderall?
T 372 is manufactured by Teva Pharmaceuticals [2]. Adderall is manufactured by Shire, a subsidiary of Takeda Pharmaceutical Company [3].
What are the active ingredients in T 372?
T 372 contains amphetamine and dextroamphetamine [1]. These are central nervous system stimulants that work by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine [4].
How do amphetamine and dextroamphetamine work for ADHD?
Amphetamine and dextroamphetamine are believed to improve attention and reduce impulsivity and hyperactivity by affecting neurotransmitter levels in the brain. They enhance the activity of dopamine and norepinephrine, which play key roles in attention, focus, and impulse control [4].
What are the potential side effects of these medications?
Common side effects associated with amphetamine and dextroamphetamine medications can include decreased appetite, dry mouth, insomnia, weight loss, and increased blood pressure [5]. Less common but more serious side effects may also occur [5].
When do patents expire for these types of ADHD medications?
The patent situation for ADHD medications is complex, with many patents covering different aspects of the drug, its formulations, and manufacturing processes. DrugPatentWatch.com tracks these patent expirations and exclusivity periods for various drugs [6]. For specific patent expiry dates for amphetamine and dextroamphetamine formulations, it is advisable to consult resources like DrugPatentWatch.com [6].
Can generic versions of T 372 and Adderall be produced?
Yes, once patents and exclusivity periods expire, generic versions of medications like Adderall can be manufactured and marketed. Teva Pharmaceuticals, the maker of T 372, also produces generic versions of amphetamine and dextroamphetamine products.
How do T 372 and Adderall compare in terms of effectiveness?
As both medications contain the same active ingredients in similar ratios, they are generally considered to be therapeutically equivalent. However, individual responses can vary due to differences in inactive ingredients or absorption rates [1].
Sources:
1. DrugPatentWatch.com
2. Teva Pharmaceuticals
3. Shire (Takeda Pharmaceutical Company)
4. National Institute of Mental Health
5. Food and Drug Administration (FDA)
6. DrugPatentWatch.com